#Scinai Immunotherapeutics #Israel #Jerusalem #CDMO #Amir Reichman

Scinai Immunotherapeutics Reports Corporate Highlights

Scinai Immunotherapeutics Ltd., publicly traded on NASDAQ under the ticker symbol SCNI, recently provided an overview of its corporate performance and financial results for the first half of 2026. The presentation showcased notable advancements within the company's CDMO (contract development and manufacturing organization) segment, indicating a strengthening position in the biopharmaceutical sector.

Key Corporate Developments

On August 26, Scinai plans to host an informative webinar for investors, aimed at discussing recent company developments, financial results, and strategic milestones moving forward. One of the significant achievements reported is that Scinai has managed to accumulate approximately $3.1 million in committed customer orders as of mid-August 2026. Out of this, around $2.1 million has already been invoiced. This influx of orders represents a growing client base and reflects a positive trajectory for the company’s CDMO activities.

In particular, Scinai has made headway in an expanded clinical manufacturing program in collaboration with a U.S.-based biopharmaceutical firm. The partnership builds on pre-existing contractual relationships and aims to support an investigational drug product aimed at securing U.S. IND submission and progressing into Phase III clinical development. Approximately $650,000 in cash payments associated with this initiative have already been received, indicating robust activity while strategic negotiations for the definitive agreement continue.

The company's management remains optimistic about achieving approximately $5 million in CDMO revenues for the entirety of 2026. The focus for Scinai remains steadfast on employing innovative strategies to bolster operational capability and improve revenue conversion rates.

Financial Performance Overview

Scinai's financial results for the first half of 2026 reveal a revenue increase to $949,000, up from $773,000 during the same period the previous year. This rise in revenue is largely attributed to the integration of the Yavne operations, which expanded the company’s operational footprint and service offerings. However, it's important to note that revenue availability reflects only those customer contracts for which Scinai has met applicable service performance metrics so far into the reporting period.

Despite the growth in revenue, the cost of revenues increased significantly to $3.3 million, up from approximately $2 million the previous year due to the enhancement of the company’s CDMO infrastructure and increased operational costs associated with the Yavne acquisition. This has resulted in a gross loss of approximately $2.4 million, deeper than the previous gross loss of $1.3 million due to escalating operational expenses.

Research and development expenditure decreased to nearly $800,000 from $1.2 million, as the company redirected resources towards its CDMO segment activities while maintaining some focus on therapeutic development programs.

In terms of operational losses, Scinai reported around $4.6 million, up from $3.8 million in the first half of 2025. Interestingly, net income swung positively to approximately $1.6 million, recovering from a net loss of around $4.1 million in the prior year. This shift was mainly driven by an unexpected bargain purchase gain worth $6.4 million associated with the acquisition of Recipharm Israel.

Cash liquidity positions remain robust, with total cash resources at approximately $2.9 million as of June 30, 2026. This improved cash position reflects the acquired cash from Recipharm and enables Scinai to support ongoing operations and strategic investments effectively.

CEO’s Insight

Amir Reichman, the CEO of Scinai, commented on the findings, stating, “The first half of 2026 was focused on expanding and integrating our CDMO platform. As we move through the second half of the year, our focus will increasingly shift to commercial execution, enhancing facility utilization, and turning our built capabilities into tangible revenue.” He emphasized the significance of expanding existing U.S. customer engagements into broader manufacturing initiatives, demonstrating Scinai's ability to support critical clinical development programs.

The company remains dedicated to converting its commercial pipeline into measurable revenue while continuing to advance therapeutic programs such as PC111 and the NanoAbs platform. Upcoming initiatives, including participation in a potential Polish FENG funding round, will support these objectives.

In conclusion, Scinai Immunotherapeutics appears poised for a progressive trajectory as it seeks to further optimize its operations, enhance customer relationships, and solidify its standing in the biopharmaceutical industry, inviting stakeholders to be engaged during the upcoming investor webinar that promises to expand on these themes.